
Pharmaceutical firm leveraging deuterium chemistry for superior, patent-protected products.
Lennham Pharmaceuticals was founded with the mission to enhance the metabolic and pharmacological profiles of drugs through the innovative use of deuterium chemistry. The company focuses on creating pharmaceutical products that exhibit superior metabolic or pharmacokinetic properties, offering significant improvements over existing treatments. Lennham's approach involves identifying chemical compounds that can benefit from deuterium modification, resulting in products with strong patent protection and potentially better therapeutic outcomes.
The company is led by a team of industry experts dedicated to leveraging this underutilized technology. Lennham Pharmaceuticals has achieved notable success in developing improved pharmaceutical products, securing robust patent protection for their innovations. Their work has had a significant impact on the pharmaceutical industry by introducing more effective and safer drugs, thereby improving patient outcomes and setting new standards in drug development.

DeuteRx
deuterx.com

Synthonics
synthonicsinc.com

Auxilius Pharma
auxiliuspharma.com

Handa Pharmaceuticals
handapharma.com

Woolsey Pharmaceuticals
woolseypharma.com

Plumb Pharmaceuticals
plumbpharma.com

PleoPharma
pleopharma.com

Marius Pharmaceuticals
mariuspharma.com

6S Pharma
6spharma.com

Dauntless Pharmaceuticals

LB Pharmaceuticals
lbpharma.us

Lenz Therapeutics
lenz-tx.com

Thar Pharmaceuticals
tharpharma.com

PIN Pharma
pinpharma.com

OrphoMed
orphomed.com

Deltanoid Pharmaceuticals

Essential Remedium

Housey Pharmaceutical Research Laboratories
housey.com
Ammonett Pharma

Lewis and Clark Pharmaceuticals
Lennham Pharmaceuticals' most recent funding round was for $1.2M (USD) in April 2023.
As of Apr 3, 2023, Lennham Pharmaceuticals has disclosed funding of $3.5M (USD).